Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Blood AdvancesOpen Access

Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1

View Full Paper
Ask AI
Bookmark
Share

Authors

CSCarolina SchinkePRPaula Rodríguez‐OteroNDNiels W.C.J. van de Donk

Discussion

Loading...

Member takes

Overview

Phase 1/2 MonumenTAL-1 trial explores infection rates and humoral immunity with talquetamab, suggesting its potential as a safer treatment for RRMM patients.

Key Points

  • Talquetamab treatment resulted in relatively low rates of grade 3/4 infections among patients with relapsed multiple myeloma.
  • Infections were reported in 58.7% to 72.5% of patients, with respiratory infections being the most common.
  • Neutrophil levels recovered by cycle 2 and immunoglobulin G levels were stable, enhancing treatment safety.
  • Relatively few patients required intravenous immunoglobulin therapy after receiving talquetamab for their disease.

Cite This Study

Schinke et al. (2025) studied this question.

synapsesocial.com/papers/68c2384fb210217d647771dehttps://doi.org/10.1182/bloodadvances.2025016613
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials2025 · 1 citations
  2. 2Talquetamab outcomes from practice outside of clinical trials: The bital study2025
  3. 3Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study2025 · 18 citations
  4. 4Real‑world matched comparison of talquetamab versus teclistamab in Relapsed/Refractory multiple myeloma2025
  5. 5Dermatologic toxicities associated with talquetamab in patients with Relapsed/Refractory multiple myeloma: A systematic review and meta-analysis2025